Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00349401
Recruitment Status : Withdrawn (Study was not initiated. No subjects were screened or enrolled.)
First Posted : July 7, 2006
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):
Wake Forest University Health Sciences

July 5, 2006
July 7, 2006
November 6, 2017
December 2006
Not Provided
  • VAS pain.
  • Primary analysis will be the comparison between ketorolac and placebo groups.
Same as current
Complete list of historical versions of study NCT00349401 on Archive Site
Change in oral opioid dose.
Same as current
Not Provided
Not Provided
Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation
Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation
The purpose of this study is to determine how the drug ketorolac, when given with the spinal morphine, affects pain.

This study is part of a pain center grant that focuses on how pain, especially chronic neuropathic pain, alters the response to traditional and non-traditional analgesics (pain medications).

To treat persons with chronic pain, doctors sometimes implant a permanent tube in the spinal space in the back to give pain medicines. This tube, also called a spinal pump, is used to administer pain medicine directly to the spinal space. The most commonly used medicine given through the spinal pump is morphine which works well for most people, but sometimes loses tolerance, and larger and larger doses are needed, causing many side effects.

The purpose of this study is to find out if another medicine, ketorolac, when given with morphine in the spinal space, can stop or reverse the need for larger and larger doses of morphine. In animals, ketorolac has been shown to slow the need for an increase in morphine dosage and to reduce the morphine dose, while giving good pain control.

This study will enroll 30 individuals with chronic pain below the chest, caused by nerve injury, who are receiving morphine through a spinal pump. After learning to estimate pain accurately using thermal heat testing, participants will be randomly assigned to one of two study groups. Group one will receive the active study medication, ketorolac, while group two receives an inactive control (placebo). All participants will receive morphine (administered through the spinal pump). Afterwards, participants will rate their levels of pain, and provide samples of their spinal fluid (taken from the spinal tube/pump) for study. The above procedure will be repeated over a 4-week period.

Duration of the study for participants is 4 weeks, and includes ten visits to the research center, each lasting less than one hour.

Phase 2
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
  • Drug: ketorolac
  • Drug: morphine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • Implanted spinal pump for at last 9 months
  • Must be receiving and the dose must have been doubled in the past 6 months
  • Currently taking 60-200 mg morphine equivalent as oral rescue per day
  • Men and women, ages 18-70
  • Weigh no more that 250 pounds
  • Neuropathic pain

Exclusion Criteria:

  • Pregnancy
  • Unstable medical problems (heart lung, liver, kidney, or nervous system)
  • Allergy to morphine, ketorolac, or drugs which may be used to treat side effects
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
P01NS041386 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Not Provided
Principal Investigator: James C. Eisenach, M.D. Wake Forest University Health Sciences
Principal Investigator: Richard Rauck, M.D. The Center for Clinical Research
Wake Forest University Health Sciences
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP